Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib

What Was Tested

The trial (phase 1) is built around Tirzepatide.

It had 1 arm (groups): Tirzepatide Treatment (experimental).

The registry classes the interventions as drug.

Who Took Part

30 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age ≥ 18 years.

The full record lists 2 inclusion and 9 exclusion criteria; among the exclusions: known hypersensitivity to glp-1 agonists; active, unstable psychiatric illness; current suicidal ideation; severe organ dysfunction or systemic illness.

How the Study Was Run

Design: single-group and open-label.

Everyone knew when Tirzepatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2026-10 with completion listed for 2030-06.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Body weight changes (time frame: 1 year post treatment start). Lipid changes (time frame: 1 year post treatment start). Change in Cmax (time frame: 1 year post treatment start).

It also tracked 4 secondary outcomes, for example Rate of metabolic side effects, Changes in body mass composition, Changes in waist circumference and Changes in cardiometabolic markers.

What This Means in Plain Language

Put simply, this is a phase 1 trial of Tirzepatide in 30 people.

Its size is small, so on its own it can only give an early look.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, all human trials.